Morning hypertension and antihypertensive therapy

Uran Onaka, Michio Ueno, Tomoko Kajioka, Kenichi Goto, Kimika Eto, Mitsuhiro Tominaga, Takuya Tsuchihashi, Koji Fujii

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

抄録

We studied how a difference in plasma half-life of calcium channel blockers (CCBs) affects the elevation of blood pressure in the early morning. In this study, we analyzed the data of outpatients under treatment of essential hypertension with CCB, who measured their blood pressures at home at wake-up time, during the day and before going to bed. In those who received a CCB with short-lasting actions, we changed it to nilvadipine (Nivadil®), a CCB with long-lasting actions to evaluate changes in blood pressure elevation before and after the change. Results are shown below. Blood pressure elevation in the early morning was evaluated by comparing the blood pressure values at wake-up time and those during the day. In the evaluation, we categorized the subjects into the following three groups: short-lasting CCB group; those treated with a CCB with a short plasma half-life or a CCB with a once -daily regimen at longest; long-lasting CCB group; the subjects treated with a CCB with a long plasma half-life or a CCB with a twice-daily regimen at shortest; and non-medication group; those with no serious health risks other than blood pressure and treated only by lifestyle modification. As a result of the evaluation, SBP/DBP in the short-lasting CCB group was 12.7 ± 10.5/7.9 ± 6.5 mmHg, SBP/DBP in the long-lasting CCB group was 7.9 ± 11.6/4.6 ± 5.9 mmHg, and SBP/DBP in the non-medication group was 2.4 ± 6.0/2.8 ± 2.7 mmHg. The blood pressure elevation of SBP and DBP in the short-lasting CCB group was significantly greater than that in the other groups. We also evaluated blood pressure elevation in the early morning by comparing the blood pressure values at wake-up time and those before going to bed. As a result, SBP/DBP in the short-lasting CCB group was 10.8 ± 10.5/7.9 ± 6.3 mmHg, SBP/DBP in the long-lasting CCB group was 8.2 ± 11.4/5.9 ± 5.5 mmHg, and SBP/DBP in the non-medication group was 4.8 ± 4.8/5.6 ± 3.2 mmHg. As can be seen in the differences between the wake-up time and daytime, the blood pressure elevation in the short-lasting CCB group was greater than that in the other two groups. The blood pressure values measured at home before a change into nilvadipine were as follows: SBP/DBP at wake-up time was 148.9/92.2 mmHg, SBP/DBP during the day was 133.4/82.4 mmHg, and SBP/DBP before going to bed was 136.8/82.3 mmHg. Those after the change were as follows: SBP/DBP at wake-up time was 143.7/89.3 mmHg, SBP/DBP during the day was 133.0/81.3 mmHg, and SBP/DBP before going to bed was 135.4/81.2 mmHg. Although no changes were observed in the blood pressures during the day and before going to bed, both SBP and DBP at wake-up time were lowered significantly. The results stated above indicate that blood pressure elevation in the early morning is, in some cases, caused by pharmacokinetics of an antihypertensive drug. We have therefore concluded that it is important to take pharmacokinetics into consideration in selecting an antihypertensive drug and administration method.

元の言語英語
ページ(範囲)1857-1866
ページ数10
ジャーナルTherapeutic Research
24
発行部数9
出版物ステータス出版済み - 1 1 2003

Fingerprint

Calcium Channel Blockers
Antihypertensive Agents
Hypertension
Blood Pressure
nilvadipine
Therapeutics
L-Type Calcium Channels
Half-Life
Pharmacokinetics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

これを引用

Onaka, U., Ueno, M., Kajioka, T., Goto, K., Eto, K., Tominaga, M., ... Fujii, K. (2003). Morning hypertension and antihypertensive therapy. Therapeutic Research, 24(9), 1857-1866.

Morning hypertension and antihypertensive therapy. / Onaka, Uran; Ueno, Michio; Kajioka, Tomoko; Goto, Kenichi; Eto, Kimika; Tominaga, Mitsuhiro; Tsuchihashi, Takuya; Fujii, Koji.

:: Therapeutic Research, 巻 24, 番号 9, 01.01.2003, p. 1857-1866.

研究成果: ジャーナルへの寄稿記事

Onaka, U, Ueno, M, Kajioka, T, Goto, K, Eto, K, Tominaga, M, Tsuchihashi, T & Fujii, K 2003, 'Morning hypertension and antihypertensive therapy', Therapeutic Research, 巻. 24, 番号 9, pp. 1857-1866.
Onaka U, Ueno M, Kajioka T, Goto K, Eto K, Tominaga M その他. Morning hypertension and antihypertensive therapy. Therapeutic Research. 2003 1 1;24(9):1857-1866.
Onaka, Uran ; Ueno, Michio ; Kajioka, Tomoko ; Goto, Kenichi ; Eto, Kimika ; Tominaga, Mitsuhiro ; Tsuchihashi, Takuya ; Fujii, Koji. / Morning hypertension and antihypertensive therapy. :: Therapeutic Research. 2003 ; 巻 24, 番号 9. pp. 1857-1866.
@article{132b60fc1d5d46b981aa10bc91be8724,
title = "Morning hypertension and antihypertensive therapy",
abstract = "We studied how a difference in plasma half-life of calcium channel blockers (CCBs) affects the elevation of blood pressure in the early morning. In this study, we analyzed the data of outpatients under treatment of essential hypertension with CCB, who measured their blood pressures at home at wake-up time, during the day and before going to bed. In those who received a CCB with short-lasting actions, we changed it to nilvadipine (Nivadil{\circledR}), a CCB with long-lasting actions to evaluate changes in blood pressure elevation before and after the change. Results are shown below. Blood pressure elevation in the early morning was evaluated by comparing the blood pressure values at wake-up time and those during the day. In the evaluation, we categorized the subjects into the following three groups: short-lasting CCB group; those treated with a CCB with a short plasma half-life or a CCB with a once -daily regimen at longest; long-lasting CCB group; the subjects treated with a CCB with a long plasma half-life or a CCB with a twice-daily regimen at shortest; and non-medication group; those with no serious health risks other than blood pressure and treated only by lifestyle modification. As a result of the evaluation, SBP/DBP in the short-lasting CCB group was 12.7 ± 10.5/7.9 ± 6.5 mmHg, SBP/DBP in the long-lasting CCB group was 7.9 ± 11.6/4.6 ± 5.9 mmHg, and SBP/DBP in the non-medication group was 2.4 ± 6.0/2.8 ± 2.7 mmHg. The blood pressure elevation of SBP and DBP in the short-lasting CCB group was significantly greater than that in the other groups. We also evaluated blood pressure elevation in the early morning by comparing the blood pressure values at wake-up time and those before going to bed. As a result, SBP/DBP in the short-lasting CCB group was 10.8 ± 10.5/7.9 ± 6.3 mmHg, SBP/DBP in the long-lasting CCB group was 8.2 ± 11.4/5.9 ± 5.5 mmHg, and SBP/DBP in the non-medication group was 4.8 ± 4.8/5.6 ± 3.2 mmHg. As can be seen in the differences between the wake-up time and daytime, the blood pressure elevation in the short-lasting CCB group was greater than that in the other two groups. The blood pressure values measured at home before a change into nilvadipine were as follows: SBP/DBP at wake-up time was 148.9/92.2 mmHg, SBP/DBP during the day was 133.4/82.4 mmHg, and SBP/DBP before going to bed was 136.8/82.3 mmHg. Those after the change were as follows: SBP/DBP at wake-up time was 143.7/89.3 mmHg, SBP/DBP during the day was 133.0/81.3 mmHg, and SBP/DBP before going to bed was 135.4/81.2 mmHg. Although no changes were observed in the blood pressures during the day and before going to bed, both SBP and DBP at wake-up time were lowered significantly. The results stated above indicate that blood pressure elevation in the early morning is, in some cases, caused by pharmacokinetics of an antihypertensive drug. We have therefore concluded that it is important to take pharmacokinetics into consideration in selecting an antihypertensive drug and administration method.",
author = "Uran Onaka and Michio Ueno and Tomoko Kajioka and Kenichi Goto and Kimika Eto and Mitsuhiro Tominaga and Takuya Tsuchihashi and Koji Fujii",
year = "2003",
month = "1",
day = "1",
language = "English",
volume = "24",
pages = "1857--1866",
journal = "Therapeutic Research",
issn = "0289-8020",
publisher = "Life Science Publishing Co. Ltd",
number = "9",

}

TY - JOUR

T1 - Morning hypertension and antihypertensive therapy

AU - Onaka, Uran

AU - Ueno, Michio

AU - Kajioka, Tomoko

AU - Goto, Kenichi

AU - Eto, Kimika

AU - Tominaga, Mitsuhiro

AU - Tsuchihashi, Takuya

AU - Fujii, Koji

PY - 2003/1/1

Y1 - 2003/1/1

N2 - We studied how a difference in plasma half-life of calcium channel blockers (CCBs) affects the elevation of blood pressure in the early morning. In this study, we analyzed the data of outpatients under treatment of essential hypertension with CCB, who measured their blood pressures at home at wake-up time, during the day and before going to bed. In those who received a CCB with short-lasting actions, we changed it to nilvadipine (Nivadil®), a CCB with long-lasting actions to evaluate changes in blood pressure elevation before and after the change. Results are shown below. Blood pressure elevation in the early morning was evaluated by comparing the blood pressure values at wake-up time and those during the day. In the evaluation, we categorized the subjects into the following three groups: short-lasting CCB group; those treated with a CCB with a short plasma half-life or a CCB with a once -daily regimen at longest; long-lasting CCB group; the subjects treated with a CCB with a long plasma half-life or a CCB with a twice-daily regimen at shortest; and non-medication group; those with no serious health risks other than blood pressure and treated only by lifestyle modification. As a result of the evaluation, SBP/DBP in the short-lasting CCB group was 12.7 ± 10.5/7.9 ± 6.5 mmHg, SBP/DBP in the long-lasting CCB group was 7.9 ± 11.6/4.6 ± 5.9 mmHg, and SBP/DBP in the non-medication group was 2.4 ± 6.0/2.8 ± 2.7 mmHg. The blood pressure elevation of SBP and DBP in the short-lasting CCB group was significantly greater than that in the other groups. We also evaluated blood pressure elevation in the early morning by comparing the blood pressure values at wake-up time and those before going to bed. As a result, SBP/DBP in the short-lasting CCB group was 10.8 ± 10.5/7.9 ± 6.3 mmHg, SBP/DBP in the long-lasting CCB group was 8.2 ± 11.4/5.9 ± 5.5 mmHg, and SBP/DBP in the non-medication group was 4.8 ± 4.8/5.6 ± 3.2 mmHg. As can be seen in the differences between the wake-up time and daytime, the blood pressure elevation in the short-lasting CCB group was greater than that in the other two groups. The blood pressure values measured at home before a change into nilvadipine were as follows: SBP/DBP at wake-up time was 148.9/92.2 mmHg, SBP/DBP during the day was 133.4/82.4 mmHg, and SBP/DBP before going to bed was 136.8/82.3 mmHg. Those after the change were as follows: SBP/DBP at wake-up time was 143.7/89.3 mmHg, SBP/DBP during the day was 133.0/81.3 mmHg, and SBP/DBP before going to bed was 135.4/81.2 mmHg. Although no changes were observed in the blood pressures during the day and before going to bed, both SBP and DBP at wake-up time were lowered significantly. The results stated above indicate that blood pressure elevation in the early morning is, in some cases, caused by pharmacokinetics of an antihypertensive drug. We have therefore concluded that it is important to take pharmacokinetics into consideration in selecting an antihypertensive drug and administration method.

AB - We studied how a difference in plasma half-life of calcium channel blockers (CCBs) affects the elevation of blood pressure in the early morning. In this study, we analyzed the data of outpatients under treatment of essential hypertension with CCB, who measured their blood pressures at home at wake-up time, during the day and before going to bed. In those who received a CCB with short-lasting actions, we changed it to nilvadipine (Nivadil®), a CCB with long-lasting actions to evaluate changes in blood pressure elevation before and after the change. Results are shown below. Blood pressure elevation in the early morning was evaluated by comparing the blood pressure values at wake-up time and those during the day. In the evaluation, we categorized the subjects into the following three groups: short-lasting CCB group; those treated with a CCB with a short plasma half-life or a CCB with a once -daily regimen at longest; long-lasting CCB group; the subjects treated with a CCB with a long plasma half-life or a CCB with a twice-daily regimen at shortest; and non-medication group; those with no serious health risks other than blood pressure and treated only by lifestyle modification. As a result of the evaluation, SBP/DBP in the short-lasting CCB group was 12.7 ± 10.5/7.9 ± 6.5 mmHg, SBP/DBP in the long-lasting CCB group was 7.9 ± 11.6/4.6 ± 5.9 mmHg, and SBP/DBP in the non-medication group was 2.4 ± 6.0/2.8 ± 2.7 mmHg. The blood pressure elevation of SBP and DBP in the short-lasting CCB group was significantly greater than that in the other groups. We also evaluated blood pressure elevation in the early morning by comparing the blood pressure values at wake-up time and those before going to bed. As a result, SBP/DBP in the short-lasting CCB group was 10.8 ± 10.5/7.9 ± 6.3 mmHg, SBP/DBP in the long-lasting CCB group was 8.2 ± 11.4/5.9 ± 5.5 mmHg, and SBP/DBP in the non-medication group was 4.8 ± 4.8/5.6 ± 3.2 mmHg. As can be seen in the differences between the wake-up time and daytime, the blood pressure elevation in the short-lasting CCB group was greater than that in the other two groups. The blood pressure values measured at home before a change into nilvadipine were as follows: SBP/DBP at wake-up time was 148.9/92.2 mmHg, SBP/DBP during the day was 133.4/82.4 mmHg, and SBP/DBP before going to bed was 136.8/82.3 mmHg. Those after the change were as follows: SBP/DBP at wake-up time was 143.7/89.3 mmHg, SBP/DBP during the day was 133.0/81.3 mmHg, and SBP/DBP before going to bed was 135.4/81.2 mmHg. Although no changes were observed in the blood pressures during the day and before going to bed, both SBP and DBP at wake-up time were lowered significantly. The results stated above indicate that blood pressure elevation in the early morning is, in some cases, caused by pharmacokinetics of an antihypertensive drug. We have therefore concluded that it is important to take pharmacokinetics into consideration in selecting an antihypertensive drug and administration method.

UR - http://www.scopus.com/inward/record.url?scp=0141883204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141883204&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0141883204

VL - 24

SP - 1857

EP - 1866

JO - Therapeutic Research

JF - Therapeutic Research

SN - 0289-8020

IS - 9

ER -